0000-0002-1760-3516 About
Researcher specializing in molecular oncology, translational bioinformatics and precision medicine with extensive experience in investigating the molecular mechanisms underlying cancer progression, fibrosis and inflammation-associated diseases. The research focuses on interpreting the complex interactions between gene regulation, cellular signaling pathways, metabolic reprogramming and tumor microenvironment dynamics that drive disease development and therapeutic resistance.
Experienced in integrating high-throughput transcriptomics, proteomics, systems biology and multi-omics datasets with experimental molecular biology approaches to identify clinically relevant diagnostic biomarkers, prognostic signatures and novel therapeutic targets. Skilled in computational biology, network pharmacology and bioinformatics driven analyses for understanding disease mechanisms and translating molecular findings into potential clinical applications.
Research expertise includes the study of epithelial–mesenchymal transition (EMT), cancer metabolism, FGFR signaling pathways and microRNA-mediated regulation in hepatocellular carcinoma and breast cancer. Currently leading investigations into the therapeutic potential plant-derived bioactive compounds and targeted molecular therapies through integrated computational and experimental validation strategies.
Also experienced in applying machine learning and predictive modeling approaches for biomarker discovery, early disease detection and precision oncology. Dedicated to advancing precision oncology through interdisciplinary research that bridges computational analytics with experimental and clinical cancer biology.
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (7)
- Exploring the mechanisms of epithelial-mesenchymal transition (EMT) in breast cancer: The role of MicroRNA and the therapeutic promise of bioactive compounds from edible plants Save
- Increased expression of FGF14 and SCN2A/SCN11A is associated with better survival of HCC patients Save
- FGF21 affects the glycolysis process via mTOR-HIF1α axis in hepatocellular carcinoma Save
- Exploring the Anticancer Potential of Astragalin in Triple Negative Breast Cancer Cells by Attenuating Glycolytic Pathway through AMPK/mTOR Save
- Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients Save
- Effect of MHC Linked 7-Gene Signature on Delayed Hepatocellular Carcinoma Recurrence Save
- Targeted Inhibition of Fibroblast Growth Factor Receptor 1-GLI Through AZD4547 and GANT61 Modulates Breast Cancer Progression Save